Thursday, January 21, 2021

PRESS RELEASES

NICO.LAB Ready to Revolutionize U.S. Stroke Care After FDA Clearance

NICO.LAB Ready to Revolutionize U.S. Stroke Care Following FDA Clearance

AMSTERDAM/PRNewswire/ — StrokeViewer enables physicians to provide every stroke patient with the right treatment, as fast as possible. Two million brain cells die every minute until blood flow is restored (Saver, 2006), starting treatment earlier can make the difference between recovery or life-long disability.

Date of Release: Nov. 26, 2020 

This week the FDA approved a 510k application (FDA K200873) for StrokeViewer LVO, an artificial intelligence algorithm for fast triaging of stroke patients. StrokeViewer LVO detects image characteristics associated with a Large Vessel Occlusion (LVO) and alerts physicians. The FDA application was supported by a multi-center clinical study where the performance of the algorithm was retrospectively evaluated in 384 patients from multiple US stroke centers. An expert panel assessed the data to identify LVOs (ICA, M1 and M2) and comparison with the algorithm showed results exceeding the performance goal.

Stroke Viewer

StrokeViewer was developed by the Dutch medtech company NICO.LAB. The cloud-based solution uses artificial intelligence to support physicians in the emergency stroke setting. The FDA-cleared LVO algorithm is embedded in a cloud-based system that sends a notification to the medical specialists involved just minutes after a stroke patient arrives in the hospital. The physicians are able to use their smartphones, in the hospital but also at home, to inspect the CT images in a web viewer and diagnose stroke.

“Medical specialists are under enormous pressure to make fast decisions day and night, but it’s not easy. Complicated assessment and interhospital communication sadly make life difficult for physicians motivated to treat stroke victims effectively” – said Merel Boers, CEO and co-founder of NICO.LAB. “With our first FDA clearance we are now able to show U.S. physicians how impactful the combination of human and artificial intelligence is. And yes, more will follow as we are fully committed to unlocking the full healthcare potential for every patient.”

StrokeViewer is currently in use in Australia and Europe where it has proven to reduce the time from hospital arrival to start treatment for patients with acute stroke, leading to reduced patient disability in the short-term and more clot removal treatments performed.

Stroke is a leading cause for serious long-term disability in the United States. The economic burden of stroke exceeds an astonishing $100 billion per annum (Girotra, Lekoubou et al., 2020). Stroke incidence and associated costs are rising drastically due to an aging population and increasing unhealthy lifestyle. NICO.LAB is dedicated to playing a crucial role in reducing stroke related costs and improving quality of life of patients by combining human and artificial intelligence to revolutionize emergency stroke care.

About

NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Center in the Netherlands. An international team of researchers, developers and physicians connects human & artificial intelligence to empower physicians in emergency care with end-to-end solutions. The company is active in Europe, Asia, Australia and the United States. StrokeViewer consists of a set of tools to support the entire stroke workflow. StrokeViewer LVO is the first with FDA approval. Local availability of StrokeViewer functionality is subject to applicable CE marking, TGA and FDA approval (actual status on www.nico-lab.com).

References
Saver, 2006 – “Time is brain—quantified.” Stroke 37.1 (2006): 263-266
FDA K200873 – StrokeViewer LVO is approved as HALO under FDA submission number K200873
Girotra, Lekoubou et al. 2020 – “A contemporary and comprehensive analysis of the costs of stroke in the United States” JNS-journal, volume 410, 116643

Contact

Mike Moolenbel
Head of Marketing & Communications
mmoolenbel@nico-lab.com
+31642228955

Related Images

nico-lab.jpg
NICO.LAB
NICO.LAB logo

strokeviewer.jpg
StrokeViewer
StrokeViewer logo

merel-boers-ceo-founder.jpg
Merel Boers (CEO & Founder)
Merel Boers (CEO & Founder)

strokeviewer-lvo.jpg
StrokeViewer LVO
StrokeViewer on smartphone

Related Links

NICO.LAB website

NICO.LAB LinkedIn page

Related Video

SOURCE NICO.LAB B.V.

PATIENT ADVISORY

Medika Life has provided this material for your information. It is not intended to substitute for the medical expertise and advice of your health care provider(s). We encourage you to discuss any decisions about treatment or care with your health care provider. The mention of any product, service, or therapy is not an endorsement by Medika Life

Medika Lifehttps://medika.life
Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Read more Releases

Hyper-Transmissible SARS-CoV-2 Variant Detected in U.S. Wastewater

The SARS-CoV-2 B1.1.7 (UK Variant) test is available immediately both as a fee-for-service and as a complete, ready-to-use PCR kit for testing labs.

Alterity and UniQuest Partner to Reverse Bacterial Resistance to Antibiotics

Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

Never-Before-Seen COVID-19 Data Report Released by HHS

HHS has just released the "COVID Community Profile Report," a daily updated snapshot of how COVID-19 is affecting our states and communities

Stroke and Altered Mental State Increase Risk of Death for COVID-19 Patients

People hospitalized with COVID-19 and neurological problems including stroke and confusion, have a higher risk of dying than other COVID-19 patients

Study Reveals Networks of Genes Involved in Congenital Heart Disease

Over two million babies, children, and adults in the United States are living with congenital heart disease—a range of birth defects affecting the heart's structure or function

An Unexpected Role for the Brain’s Immune Cells

An important part of the brain's immune system, cells called microglia constantly extend and retract "branches" from their cell body to survey their environment.

RECENT PRESS RELEASES

NEED MORE EXPOSURE?

Want your companies products and services advertised across Medika's platform? We offer various packages from a free 3 month trial to an Enterprise package for larger companies fielding multiple brands,

%d bloggers like this: